Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage by Aggarwal, Anita et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Thrombosis Journal
Open Access Case report
Recombinant activated factor VII (rFVIIa) as salvage treatment for 
intractable hemorrhage
Anita Aggarwal*1, Vera Malkovska1, Joseph P Catlett1 and Kirsten Alcorn2
Address: 1Washington Cancer Institute, Washington Hospital Center, 110 Irving Street, NW, Washington, District of Columbia, 20010, United 
States of America and 2Dept of Pathology and Laboratory Medicine, Washington Hospital Center, 110 Irving Street, NW, Washington, District of 
Columbia, 20010, United States of America
Email: Anita Aggarwal* - anita.aggarwal@medstar.net; Vera Malkovska - vera.malkovska@medstar.net; 
Joseph P Catlett - joseph.p.catlett@medstar.net; Kirsten Alcorn - kirsten.alcorn@medstar.net
* Corresponding author    
Abstract
Background: Recently, there has been an increased use of recombinant activated factor VII
(rFVIIa) to promote hemostasis in various hemorrhagic conditions. The objective of this study was
to determine the outcome of patients treated with rFVIIa who had intractable bleeding associated
with cardiac surgery (CSP) or as a result of other causes (OBP).
Methods:  The medical records of 40 consecutive patients treated with rFVIIa were
retrospectively reviewed for blood product use before and after treatment. In all patients, rFVIIa
was given only after all other measures to stop bleeding had failed. The number of transfused units
of red cells (R), platelets (P), fresh frozen plasma (F), and cryoprecipitate (C) were determined both
before and after administration of rFVIIa, and the results compared. Mortality at 4 hours and 30
days was assessed. Patients dying within 4 hours of rFVIIa administration were not evaluable for
response. Patient characteristics were also assessed as risk factors for mortality.
Results: Twelve of 24 CSP survived for more than 4 hours. These 12 patients required an average
of 17 units (U) of R, 18 U of P, 18 U of F and 15 U of C pre-treatment compared to an average of
6 U, 10 U, 9 U and 4 U of R, P, F and C respectively, post-treatment. These differences were
statistically significant. For the OBP, 11 of 16 survived more than four hours. These 11 patients
required an average of 10 U of R, 11 U of P, 14 U of F and 10 U of C pretreatment compared to
an average of 1 U, 2 U, 2 U and 0 U of R, P, F, and C respectively, post-treatment. With the
exception of C, there was a statistically significant decrease in blood product use following
treatment with rFVIIa. Of the survivors in each group, 6 of 12 CSP and 2 of 11 OBP died between
3 and 30 days post-treatment from causes other than bleeding. Mortality at 30 days for CSP and
OBP survivors was 50% and 18% respectively, whereas overall 30 day mortality was 75% for CSP
and 44% for OBP.
Conclusions: rFVIIa is effective in decreasing blood product use and promoting hemostasis in
patients with intractable bleeding associated with cardiac surgery and a variety of other causes.
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Introduction
Recombinant factor VIIa (rFVIIa), originally developed for
the treatment of acquired inhibitors associated with
hemophilia [1,2], has been successfully used for bleeding
due to acquired or congenital thrombocytopathy [3,4],
extensive trauma and a variety of surgical procedures,
including anecdotal reports of use in cardiac surgery
patients [5-9]. It reverses the effect of warfarin in healthy
volunteers [10], and corrects the prothrombin time in
patients with hepatic failure [11].
Most critically ill patients with trauma suffer profound
coagulopathy. Coagulation abnormalities in these
patients have been attributed to multiple factors including
disseminated intravascular coagulation (DIC), excessive
fibrinolysis due to release of tissue plasminogen activator
(tPA), dilutional coagulopathy from fluid replacement
and massive blood product transfusion, dysfunctional
platelets, and metabolic abnormalities including acidosis
and hypothermia [12-18]. In addition, the use of cardiop-
ulmonary bypass in patients undergoing cardiac surgical
procedure may exacerbate the coagulopathy [19].
Although the mechanism of action of rFVIIa remains
unclear, many investigators have suggested that it binds to
the surface of activated platelets and directly activates Fac-
tor X, thus bypassing the early steps of the coagulation cas-
cade. Activated Factor X (Xa) then combines with
activated Factor V (Va) on the platelet surface, leading to
rapid conversion of prothrombin to thrombin [20,21].
Hemostasis is promoted through high concentrations of
thrombin generated near activated platelets at the site of
vascular injury. Based on its mechanism of action, rFVIIa
may be effective in controlling hemorrhage due to
trauma, surgery and other causes.
The present report is a retrospective review of 40 consecu-
tive patients treated with rFVIIa (NovoSeven, Novo Nord-
isk, Denmark) for intractable hemorrhage. Twenty-four of
these patients had bleeding associated with cardiac sur-
gery, and the remaining 16 suffered with bleeding from
other causes. The need for transfusion of blood products
both before and after treatment and the mortality at 4
hour and 30 day were assessed. Patient characteristics
were also assessed as risk factors for mortality.
Methods
Patients
The study was approved by the Institutional Board Review
of the Washington Hospital Center, Washington DC,
USA. The medical records of 40 consecutive patients
treated with rFVIIa between July 2001 and June 2003 at
the Washington Hospital Center, a tertiary care teaching
hospital and level 1 trauma center, were reviewed. The
patients were divided into two groups: 24 patients who
had undergone cardiac surgical procedures (CSP), and 16
patients who had bleeding from other causes (OBP).
There were more male patients in both groups (19 males
and 5 females in CSP, 10 males and 6 females in OBP).
The median age in the CSP was higher at 65 years (range
26–85 years) compared to that of OBP (median age 42;
range 23–82 years). The type of surgery in the CSP group
included 15 coronary artery bypass grafts (CABG), 3 aortic
arch repairs either elective or for dissection, 2 aorta rup-
ture repair (one also underwent CABG), 3 valve replace-
ments and 1 ventricular rupture. In the OBP group, 5
patients had suffered either stab or gunshot wounds, 2
had traumatic liver lacerations, 2 had undergone joint
replacement, 3 had clotting factor abnormalities
(acquired Factor VIII inhibitor, congenital Factor VII defi-
ciency, acquired VWF deficiency), and one each had post
partum hemorrhage, warfarin overdose, bowel resection,
and trauma from a motor vehicle accident.
Administration of rFVIIa
Commercially available rFVIIa, (Novo-Seven, Novo Nord-
isk, Denmark) was used in all patients. There were no pre-
determined criteria for administration. In most patients,
treatment was given after extensive blood product support
had failed to control hemorrhage, and the decision to
treat was made jointly by the surgeon, hematologist and
blood bank pathologist. rFVIIa was administered as a
bolus dose of 90 mcg/kg. The first two patients received a
second dose of 90 mcg/kg 6 hours after the first.
Endpoints and Assessment of Risk
The total number of products given before and up to
twenty-four hours after rFVIIa administration, or until
death, whichever came first, was quantified. Patients who
died within 4 hours of treatment were not evaluable
because blood product support was suspended shortly
after rFVIIa administration in these hemodynamically
unstable patients deemed non-salvageable. Also, given
the short half-life of rFVIIa, this time frame did not allow
for an accurate determination of efficacy. The number of
patients surviving at 4 hours and 30 days after the admin-
istration of rFVIIa was compared. Thirty days was chosen
as an end point since this is the operative mortality cut off
point, as defined by the Society of Thoracic Surgeons, for
inpatient and out of hospital death. For patients surviving
more than 4 hours, charts were reviewed for thromboem-
bolic complications during hospitalization.
In an attempt to determine risk factors for poor outcome,
patients were assessed for age, gender, comorbid condi-
tions, left ventricular ejection fraction (LVEF), use of car-
diopulmonary bypass (CPB), hemoglobin, platelet count,
arterial blood gas results and coagulation parameters
including prothrombin time (PT), activated partial
thromboplastin time (aPTT), fibrinogen, and D-Dimers.Thrombosis Journal 2004, 2:9 http://www.thrombosisjournal.com/content/2/1/9
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Laboratory parameters were not available for some
patients.
Statistical Considerations
The Paired Student's t-Test was used to compare the
number of blood product transfusions before and after
treatment with rFVIIa, and, since the number of pair
groups was less than 50, this result was confirmed with
the Wilcoxon Matched-Pairs Signed-Ranks Test.
Results
Cardiac Surgery Patients (CSP)
Outcome
Twelve of the 24 patients survived for more than 4 hours
after the administration of rFVIIa, and the results of their
pre- and post-treatment blood product use are listed in
Table 1. From the start of surgery until the administration
of rFVIIa, patients received on average 17 U of R (range 5–
39), 18 U of P (range 6–37), 18 U of F (range 6–33), and
15 U of C (range 0–50). Post rFVIIa treatment, an average
of 6 U of R (range 0–28), 10 U of P (range 0–19), 9 U of
F (range 0–28) and 4 U of C (0–20) were transfused. The
difference between the pre- and post-transfusion require-
ment was significantly lower for all blood products: R (p
= 0.007), P (p = 0.038), F (p = 0.009) and C (p = 0.03).
Eight of the 12 patients showed a rapid hemostatic
response to rFVIIa, as measured by a decrease in R transfu-
sion to an average of 2 U (range 0–6). The other 4 patients
(Patient # 24, 27, 32 and 35) continued to require blood
product support beyond 24 hours after rFVIIa
administration.
Six of the 12 patients who survived more than four hours
were eventually discharged to home (Table 1). The
remaining 6 patients (Patient # 13, 24, 27, 30, 32, and 33)
died between 3 and 30 days after rFVIIa treatment from a
variety of causes including multi-organ failure and infec-
tions. Amongst survivors beyond 4 hours, mortality at 30
days was 50% and overall mortality for the entire group
was 75%.
Of the 12 patients who died from multiorgan failure and
hemodynamic instability within 4 hours of receiving
rFVIIa, 11 died within 2 hours and 1 died within 4 hours
(8 during surgery and 4 in the recovery room). Due to the
limited time frame, it was not possible to determine if
bleeding in these patients diminished after rFVIIa treat-
ment. In the urgent setting in which these patients were
Table 1: Summary of rFVIIa treated cardiac surgery patients (CSP) who survived >4 hours
P# Age sex Procedure Co-morbidities Response to rFVIIa Outcome
CPB EF% Pre rFVIIa Post rFVIIa
RPFCR P F C
1 75M CABG - >45 18 18 8 10 0 4 0 0 Survived
13 36M Aortic arch repair + >45 28 18 16 10 6 19 20 10 Died
14 64M Aortic dissection - >45 39 37 32 50 2 6 4 0 Survived
17 63M AVR/MVR repair - <25 7 18 16 15 1 12 6 0 Survived
18 70M CABG + >25 6 20 20 20 0 0 0 0 Survived
20 72M CABG - >25 21 12 10 0 0 0 0 0 Survived
24* 79M CABG + >25 10 12 12 10 5 4 4 0 Died
27* 64M CABG, IVAD + <25 30 30 33 20 28 16 28 20 Died
30 85M CABG, ruptured aorta + >45 13 12 6 10 3 6 8 0 Died
32* 83M CABG + >25 5 18 18 10 6 18 20 0 Died
33 78F Ruptured aorta + <25 14 18 20 20 3 12 6 0 Died
35* 54M Aortic arch repair + >45 9 6 18 10 15 24 12 20 Survived
A v e r a g e 1 71 81 81 56 1 0 9 4
P value .009 .038 .009 .03
P: Patient
R: Red Blood Cell; P: Platelet; F: Fresh Frozen Plasma; C: Cryoprecipitate
M: Male; F: Female
CPB: Cardiopulmonary Bypass
EF: Left Ventricular Ejection Fraction
CABG: Coronary Artery Bypass Graft
AVR: Aortic Valve Replacement
MVR: Mitral Valve Replacement
IVAD: Intraventricular Assisted Device
* Patient continued to require blood transfusion past 24 hours post rFVIIa treatment.Thrombosis Journal 2004, 2:9 http://www.thrombosisjournal.com/content/2/1/9
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treated, determining the amount and timing of blood loss
and blood transfusion was difficult. Moreover, for
patients deemed non-salvageable, blood product transfu-
sion was suspended before response to rFVIIa could be
determined.
Risk factors and outcome in CSP
Overall, 17 of 24 CSP were over the age of 60. Twenty
underwent CPB, and 15 had a LVEF below 25%. Fourteen
underwent mediastinal re-exploration for bleeding.
Twenty-three patients had a significant coagulopathy
defined as thrombocytopenia below 100,000/mm3, pro-
longed PT and PTT or both (data not given due to wide
variations in the results). Seven of the 24 patients did not
have a documented arterial blood gas (ABG) around the
time of rFVIIa administration; however, among the other
17 patients, pH's of 7.0 in 1, 7.2 in 5, and 7. 4 in 11
patients were noted. With regards to rFVIIa administra-
tion, there was no correlation between pH, PT, PTT,
thrombocytopenia, anemia and outcome.
Of the 12 patients who died within 4 hours, all underwent
CPB for over 30 minutes (time on CPB for 8 patients was
more than 2.5 hours). All 12 had an LVEF of less than
25% and 7 had mediastinal re-exploration for bleeding.
In contrast, only 3 of the 12 surviving patients had EF
<25%, 8 had surgery with CPB and 7 underwent medias-
tinal re-exploration. The median age and coagulation
parameters were not different between the two groups.
Other Bleeding Patients (OBP)
Outcome
Eleven of the 16 patients with bleeding due to other
causes survived for more than 4 hours after rFVIIa admin-
istration, and the results of their blood product use before
and after rFVIIa are summarized in Table 2. From the
beginning of surgery or time of trauma until the adminis-
tration of rFVIIa, patients received an average of 10 U of R
(range 2–28), 11 U of P (range 0–36), 14 U F (range 0–
34) and 10 U of C (range 0–70). Post administration of
rFVIIa, an average of 1 U of R (range 0–6), 2 U of P (range
0–6), 2 U of F (0–10) and 0 U of C were transfused over
24 hours. The difference between the pre- and post-rFVIIa
treatment blood product requirement was significantly
lower for R (p = 0.004), P (p = 0.017), and F (p = 0.017),
but not for C (p = 0.122). Nine of the 11 showed a rapid
response to rFVIIa, as measured by a decrease in R transfu-
sion to an average of <0.5 U (range 0–3). The other 2
patients (Patient # 2 and 15) continued to require blood
product support beyond 24 hours post rFVIIa treatment.
Table 2: Summary of rFVIIa treated other bleeding patients (OBP) who survived >4 hours
P# Age
Sex
Procedure Co-morbidities Response to rFVIIa Outcome
Pre rFVIIa Post rFVIIa
RPFC R P F C
2* 48F Colectomy Colon cancer 4 6 24 70 2 0 2 0 Died
15* 26F Cystectomy, nephrectomy, pelvic 
fracture, termination of Pregnancy
MVA, 20 weeks gestation 18 12 8 0 6 6 10 0 Survived
16 53M Left femur fixation Multiple myeloma 12 12 6 0 0 0 0 0 Survived
19 82M Shoulder replacement HTN, CAD, Renal failure 7 10 20 10 2 6 4 0 Survived
21 54F Liver laceration Trauma 23 17 34 20 3 6 10 0 Survived
22 24M Neck soft tissue trauma FVII deficiency 2 0 4 0 0 0 0 0 Survived
23 64F Liver laceration Dialysis 28 36 33 0 0 0 0 0 Died
28 30F Postpartum hemorrhage None 12 18 6 10 0 0 0 0 Survived
29 64M Gastrointestinal bleed FVIII inhibitor 2 0 0 0 0 0 0 0 Survived
38 60M Thyroidectomy VWF deficiency 4 12 12 4 0 0 0 0 Survived
40 40F Splenic subcapsular bleed Amyloidosis, coumadin 
overdose
4080 0 0 0 0 S u r v i v e d
Average 10 11 14 10 1 2 2 0
P value .004 .017 .017 .122
P: Patient
R: Red Blood Cell;
P: Platelet; F: Fresh Frozen Plasma; C: Cryoprecipitate
M: Male; F: Female
EF: Left Ventricular Ejection Fraction
VWF: von Willebrand Factor
* Patient continued to require blood transfusion past 24 hours post rFVIIa treatment.Thrombosis Journal 2004, 2:9 http://www.thrombosisjournal.com/content/2/1/9
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Nine of the 11 surviving patients were discharged to home
and 2 (Patient # 2 and 23) died between 3 and 30 days
from a combination of infection, cardiac arrest and multi-
organ failure. Amongst survivors beyond 4 hours, mortal-
ity at 30 days was 18% and overall mortality for the entire
group was 44%.
All five of the 16 patients who died within four hours of
rFVIIa treatment had massive injuries either from gunshot
or stab wounds. Upon arrival to the emergency room,
these patients were hemodynamically unstable, with
hemoglobin values ranging between 3–6 g/dL. rFVIIa was
given as a last resort, but these patients were not evaluable
since transfusions were suspended shortly after infusion
of rFVIIa.
Risk factors and outcome in OBP
The median age of this group was 42 years. None under-
went CPB, and two of the 7 patients tested had an EF
<25%. Only 1 patient had a second exploratory laparot-
omy for bleeding. The patient suffering with a warfarin
overdose had a splenic subcapsular bleed complicating
systemic amyloidosis.
At the time of rFVIIa administration, a wide variation in
laboratory parameters was observed in these patients
(data not shown). There was no difference in coagulation
parameters between patients who died and those who sur-
vived. Eight of the 16 patients did not have an ABG
documented. In the 5 patients who died within four
hours, the pH was lower (6.9–7.0) than for those who sur-
vived (7.3–7.4).
Thromboembolism after rFVIIa
Only one of the 23 patients in both the CSP and OBP
groups who survived more than 4 hours had a docu-
mented thromboembolic complication after receiving
rFVIIa. Deep vein thrombosis (DVT) of the left subclavian
vein was confirmed by a Doppler ultrasound 2 days after
rFVIIa administration. The thrombus was related to a cen-
tral line placed before rFVIIa treatment. No other clinical
or laboratory evidence of thromboembolism was docu-
mented in the medical records of the other patients
throughout their hospital stays. None of the other 17
patients in both the groups who died within 4 hours were
evaluable for thromboembolic complications.
Discussion
This retrospective case series suggests that rFVIIa is effec-
tive in promoting hemostasis even when given as a last
life-saving measure in poor prognosis patients with mas-
sive, transfusion-refractory hemorrhage. A statistically sig-
nificant decrease in blood product transfusion was
evident in 12 CSP and 11 OBP who survived more than 4
hours after rFVIIa infusion. Six of 12 CSP and 2 of 11 OBP
died later between 3 and 30 days after rFVIIa infusion, but
these deaths were due to causes other than hemorrhage.
Despite the obvious limitations of a retrospective analysis,
this is the largest series of such patients reported in the lit-
erature to date. Al Douri et al [8], described 5 patients who
underwent open-heart surgery for valvular disease and
experienced uncontrollable intraoperative or postopera-
tive bleeding unresponsive to a blood product support
protocol. The study was prospective, had well-defined cri-
teria for "excessive bleeding" and excluded patients with a
history of ischemic heart disease, stroke or venous throm-
boembolism. Hemostasis was achieved in all patients fol-
lowing a single dose of 30 ug/kg of rFVIIa, and there was
no mortality from bleeding, although 1 patient died 3
days later of an unrelated cause. Overall, the 4-hour and
30 day mortality in the present series was high compared
to that of Al Douri et al [8], but it is difficult to compare
these two very different patient populations.
Factors predictive of inferior outcome after cardiac surgery
include age over 60, low LVEF, significant co-morbidity,
the use of CPB and re-exploration after initial surgery [22-
24]. The use of CPB increases the rate of fibrinolysis and
induces an inflammatory response [19,25]. Moreover,
prolonged time on CPB, defined as 2.5 hours or more, is
associated with increased bleeding and need for re-explo-
ration. Two-6% of patients undergoing CABG require re-
exploration for bleeding and is associated with a mortality
rate of up to 22% [19,26,27]. In this series, the CSP group
had multiple poor prognostic factors. The median age was
65 years and in addition, all 12 of the CSP who died
within 4 hours and 3 of 6 CSP who died later had preop-
erative LVEF of less than 25%. All of the 12 CSP who died
within 4 hours in this series, required CPB and 8 of these
patients were on CPB for more than 2.5 hours. More than
half of our CSP (14 of 24) required re-exploration, which
undoubtedly influenced the mortality rate.
Both, the CSP and OBP groups had a significant decrease
in blood product use after rFVIIa treatment but the short
and long-term survival appeared to be worse in CSP prob-
ably due to multiple poor prognostic factors as discussed
above. Poor outcome has also been independently associ-
ated with peri-operative transfusion of more than 7 units
of R [28]. The CSP and OBP who survived received an
average of 18 and 11 units of R in the peri-operative
period, respectively. The R requirement of patients who
died within 4 hours in both groups was probably higher
but could not be reliably estimated. All 5 of the patients in
the OBP group who died within 4 hours suffered from
major blood vessel injury as a result of stabbing or gun
shot wounds. These patients were unstable upon arrival to
the emergency room with hemoglobins in the range of 3–
6 g/dL.Thrombosis Journal 2004, 2:9 http://www.thrombosisjournal.com/content/2/1/9
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Excessive hemorrhage requiring massive transfusion can
lead to hypothermia, DIC, excessive fibrinolysis, dilu-
tional coagulopathy, and metabolic acidosis, which may
further exacerbate bleeding and morbidity. [14-17] A
reduction in the pH to 7.0 nearly abolishes rFVIIa activity
as reported by Meng et al [18]. In this present series, there
was no obvious correlation between the coagulopathy
and mortality in both the CSP and OBP groups. Five of the
OBP who died within 4 hours had a pH of 7 or less. How-
ever, acidosis did not appear to play an important role in
CSP.
The optimal dose and timing of administration of rFVIIa
for these patients is unknown. The standard dose (90
mcg/kg) was first used in hemophiliacs and was based on
the in vitro dose-dependent reduction in aPTT in plasma
from these patients [1,29]. The 90 mcg/kg dose of rFVIIa
corresponds to concentration of 1.25 mcg/ml FVIIa in
plasma. Martinowitz et al [7], used a median dose of 120
mcg/kg (range 120–210 mcg/kg) to achieve hemostasis in
7 cases of trauma. In 2 patients, 120 mcg/kg was insuffi-
cient, and 2 additional doses of 60 mcg/kg were required
to achieve hemostasis. Kenet et al. [30], have shown better
efficacy with a 300 mcg/kg bolus dose followed by contin-
uous infusion. The standard therapeutic dose of 90 mcg/
kg of rFVIIa was used in this series of patients although a
lower dose of 30 mcg/kg dose has also been shown to be
effective [8]. However, in considering the data from the
aforementioned studies, it would appear that higher ini-
tial doses, or additional doses, might improve outcome. It
is also tempting to speculate that earlier treatment with
rFVIIa may have prevented rapid clinical deterioration
and complications associated with massive blood product
transfusion in this series of patients. This question would
best be addressed in controlled studies using standard
dosing protocols and well defined criteria for intractable
hemorrhage. Although rFVIIa is expensive, it would
appear to be cost effective when compared with the com-
bined cost of large amount of blood products.
Previous clinical experience with rFVIIa supports a good
safety profile in patients with hemophilia and trauma.
Less than 1% of patients receiving rFVIIa had thrombosis
and thrombosis related complications [21,31]. In our
series, only one patient had a deep vein thrombosis of the
left arm associated with an indwelling line and not con-
sidered to be due to rFVIIa. There were no other docu-
mented cases of thrombosis or microemboli.
Conclusions
This retrospective study suggests that rFVIIa can play a
beneficial role as an adjunctive hemostatic agent in
patients after cardiac surgery or extensive trauma who
experience bleeding that cannot be controlled by conven-
tional therapies. Prospective studies are necessary to deter-
mine optimal patient selection, and dose and timing of
rFVIIa administration.
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